Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
McKesson
AstraZeneca
Harvard Business School
Colorcon

Last Updated: November 20, 2019

DrugPatentWatch Database Preview

AVEED Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Aveed, and when can generic versions of Aveed launch?

Aveed is a drug marketed by Endo Pharms Inc and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-one patent family members in thirty-seven countries.

The generic ingredient in AVEED is testosterone undecanoate. There are sixty-nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the testosterone undecanoate profile page.

Drug patent expirations by year for AVEED
Drug Prices for AVEED

See drug prices for AVEED

Recent Litigation for AVEED

Identify potential future generic entrants

District Court Litigation
Case NameDate
Endo Pharmaceuticals Solutions Inc. v. Custopharm Inc.2014-11-21

See all AVEED litigation

Pharmacology for AVEED
Drug ClassAndrogen
Mechanism of ActionAndrogen Receptor Agonists
Synonyms for AVEED
(17-beta)-3-Oxoandrost-4-en-17-yl undecanoate
(17|A)-17-[(1-| xoundecyl)oxy]androst-4-en-3-one
(17beta)-3-Oxoandrost-4-en-17-yl undecanoate
(1S,2R,10R,11S,14S,15S)-2,15-dimethyl-5-oxotetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-en-14-yl undecanoate
(1S,2R,10R,11S,14S,15S)-2,15-dimethyl-5-oxotetracyclo[8.7.0.0?,?.0??,??]heptadec-6-en-14-yl undecanoate
[(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] undecanoate
17beta-Hydroxyandrost-4-en-3-one undecanoate
3-Oxoandrost-4-en-17beta-yl undecanoate
4-08-00-00981 (Beilstein Handbook Reference)
5-.alpha.-Androstan-3-one, 17-.beta.-hydroxy-, undecanoate
5-alpha-Androstan-3-one, 17-beta-hydroxy-, undecanoate
5949-44-0
949T440
AC1L22PV
AKOS016010255
AN-11881
Andriol
Andriol (TN)
Andriol Testocaps
Androst-4-en-3-one, 17-((1-oxoundecyl)oxy)-, (17-beta)-
Androst-4-en-3-one, 17-((1-oxoundecyl)oxy)-, (17beta)-
Androst-4-en-3-one, 17-((1-oxoundecyl)oxy)-(17beta)
Androst-4-en-3-one, 17-[(1-oxoundecyl)oxy]-, (17.beta.)-
BAY 86-5037
BCP11921
BRN 3176734
C-22555
CC-34823
CHEBI:135741
CHEMBL2107067
CLR-610
CS-4342
D06087
EINECS 227-712-6
GS-6598
H16A5VCT9C
HY-B0626
Jatenzo
LS-148824
MolPort-003-850-422
Nebido
Nebido-R
Org 538
ORG-538
Pantestone
Reandron 1000
Restandol
Rextoro
SC-16124
SCHEMBL147620
T undecanoate
Testosterone (undecanoate)
Testosterone undecanoate
Testosterone undecanoate (USAN)
Testosterone undecanoate [USAN]
Testosterone Undeconate
Testosterone undecylate
Testosterone, undecanoate
Testosterone, undecanoate (ester)
UDSFVOAUHKGBEK-CNQKSJKFSA-N
Undestor
UNII-H16A5VCT9C
W-105318
ZINC8214690
Paragraph IV (Patent) Challenges for AVEED
Tradename Dosage Ingredient NDA Submissiondate
AVEED INJECTABLE;INTRAMUSCULAR testosterone undecanoate 022219 2014-06-11

US Patents and Regulatory Information for AVEED

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Endo Pharms Inc AVEED testosterone undecanoate INJECTABLE;INTRAMUSCULAR 022219-001 Mar 5, 2014 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Endo Pharms Inc AVEED testosterone undecanoate INJECTABLE;INTRAMUSCULAR 022219-001 Mar 5, 2014 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Baxter
AstraZeneca
Colorcon
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.